Enzo Biochem’s Full Service Clinical Laboratory to Launch Coronavirus (COVID-19) Testing Services Next Week
March 06 2020 - 8:00AM
Business Wire
Enzo Clinical Labs to Begin Accepting
Specimens for COVID-19 Testing
Company Concurrently Developing Proprietary
Next Generation Test
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its wholly
owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting
specimens for novel Coronavirus (COVID-19) testing next week.
COVID-19 is a contagious virus that is believed to spread by
person-to-person transmission and may have serious health
consequences. The virus has infected more than 93,000 people
globally including recent detections in the United States. Enzo has
many years of experience processing specimens for the detection of
viral pathogens. The test used by Enzo is a molecular test that
determines the presence of viral RNA in respiratory specimens
collected from patients by healthcare providers.
Enzo CEO Dr. Elazar Rabbani commented: “Clinical laboratories
play a vital role in combatting serious challenges to public
health, including those posed by COVID-19. We are pleased to be
able to rapidly respond to the urgent need for this test and we
remain committed to working with our industry partners to address
this challenge.”
Enzo is concurrently applying its technical expertise in
molecular diagnostics to develop a next generation COVID-19 testing
option. Enzo’s innovations include virus-inactivating specimen
collection media to lessen transmission risks for healthcare
providers and clinical laboratory personnel, the development of
more relevant positive controls for the tests, and improved
sensitivity. The company is consulting with the U.S. Centers for
Disease Control and Prevention on the implementation of these
enhanced test features.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Forward-Looking
Statements
Except for historical information, the matters discussed in this
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
Such statements include declarations regarding the intent, belief
or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses which are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigation, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2019. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200306005187/en/
For: Enzo Biochem, Inc. David Bench, CFO 212-583-0100
dbench@enzo.com
Steve Anreder Anreder & Company 212-532-3232
Steven.anreder@anreder.com
Elliot Sloane ESPR LLC 917-291-0833 Elliot.espr@gmail.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024